Fusion Antibodies (LON:FAB) Releases Earnings Results

Fusion Antibodies (LON:FAB) posted its quarterly earnings data on Monday. The company reported GBX (1.20) earnings per share (EPS) for the quarter, Digital Look Earnings reports. Fusion Antibodies had a negative return on equity of 210.32% and a negative net margin of 91.92%.

Fusion Antibodies Trading Up 2.3%

Fusion Antibodies stock opened at GBX 11 on Wednesday. The company has a debt-to-equity ratio of 92.42, a quick ratio of 2.36 and a current ratio of 1.80. The stock has a 50-day simple moving average of GBX 10.82 and a 200 day simple moving average of GBX 12.14. The stock has a market capitalization of £13.77 million, a P/E ratio of -7.33 and a beta of 1.24. Fusion Antibodies has a 52 week low of GBX 9 and a 52 week high of GBX 21.

About Fusion Antibodies

Fusion is a Belfast based contract research organisation (“CRO”) providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.

The Company’s ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation. These services include antigen expression, antibody production, purification and sequencing, antibody humanisation using Fusion’s proprietary CDRx TM platform and the production of antibody generating stable cell lines to provide material for use in clinical trials.